Details of the Drug

General Information of Drug (ID: DMCULK7)

Drug Name

Lazabemide

Synonyms

103878-84-8; Ro-19-6327; N-(2-Aminoethyl)-5-chloropicolinamide; CCRIS 7301; UNII-420HD787N9; N-(2-aminoethyl)-5-chloropyridine-2-carboxamide; Ro 19-6327 hydrate; CHEMBL279390; Ro 19-6327/000; 420HD787N9; C8H10ClN3O; 2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide; NCGC00167737-01; Lazabemide [USAN:INN]; Lazabemide [USAN:INN:BAN]; Lazabemine; Pakio; Tempium; Ro-41-3776; Ro-19-6327/000; LAZEBEMIDE

Indication

Disease Entry	ICD 11	Status	REF
Skin imperfections	EK71	Patented	[1]
Cognitive impairment	6D71	Discontinued in Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

199.64

Logarithm of the Partition Coefficient (xlogp)

0.2

Rotatable Bond Count (rotbonds)

3

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

3

Chemical Identifiers

Formula: C8H10ClN3O
IUPAC Name: N-(2-aminoethyl)-5-chloropyridine-2-carboxamide
Canonical SMILES: C1=CC(=NC=C1Cl)C(=O)NCCN
InChI: InChI=1S/C8H10ClN3O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10/h1-2,5H,3-4,10H2,(H,11,13)
InChIKey: JZXRLKWWVNUZRB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71307
CAS Number: 103878-84-8
TTD ID: D06QRW

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[1]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Gene/Protein Processing	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Skin imperfections

ICD Disease Classification

EK71

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type B (MAO-B)	DTT	MAOB	2.65E-02	1.12E-02	0.07

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6640).
3	The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.
4	Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease. Clin Neuropharmacol. 1999 Nov-Dec;22(6):340-6.